Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pharmaust Limited ( (AU:NUZ) ) has shared an update.
Neurizon Therapeutics has issued 1,083,335 fully paid ordinary shares to participating directors from its September 2025 placement at $0.12 per share, following shareholder approval at the company’s November 2025 annual general meeting. The company confirmed the shares were issued without a prospectus under the Corporations Act cleansing provisions and stated it is up to date with its financial reporting and continuous disclosure obligations, with no excluded information, ensuring the new securities can trade freely and signaling continued alignment between the board and shareholders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Its lead drug candidate, NUZ-001, is being developed for amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease, with a strategy to accelerate access to effective ALS therapies while exploring broader neurodegenerative applications through international collaborations and clinical programs.
Average Trading Volume: 817,788
Technical Sentiment Signal: Sell
Current Market Cap: A$58.82M
See more insights into NUZ stock on TipRanks’ Stock Analysis page.